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Abstract
Background: In most countries of Sub-Saharan Africa, control of lymphatic filariasis (LF) is based on annual mass drug
administration (MDA) with a combination of ivermectin and albendazole. Treatment coverages are however often
suboptimal for programmes to reach the goal of transmission interruption within reasonable time. The present study aimed
to identify predictors and barriers to individual drug uptake during MDA implementation by the National LF Elimination
Programme in Tanzania.
Methods: A questionnaire based cross sectional household survey was carried out in two rural and two urban districts in
Lindi and Morogoro regions shortly after the 2011 MDA. 3279 adults ($15 years) were interviewed about personal
characteristics, socio-economic status, MDA drug uptake among themselves and their children, reasons for taking/not
taking drugs, and participation in previous MDA activities for LF control.
Findings: The overall drug uptake rate was 55.1% (range of 44.5–75.6% between districts). There was no overall major
difference between children (54.8%) and adults (55.2%) or between females (54.9%) and males (55.8%), but the role of these
and other predictors varied to some extent between study sites. Major overall predictors of drug uptake among the
interviewed adults were increasing age and history of previous drug uptake. Being absent from home during drug
distribution was the main reason for not taking the drugs (50.2%) followed by clinical contraindications to treatment
(10.8%), missing household visits of drug distributors (10.6%), and households not being informed about the distribution
(9.0%).
Conclusion: Drug uptake relied more on easily modifiable provider-related factors than on individual perceptions and
practices in the target population. Limited investments in appropriate timing, dissemination of accurate timing information
to recipients and motivation of drug distributors to visit all households (repeatedly when residents are absent) are likely to
have considerable potential for increasing drug uptake, in support of successful LF transmission elimination.
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Introduction
Lymphatic Filariasis (LF) is a mosquito transmitted parasitic
disease which in Africa is caused by the filarial nematode
Wuchereria bancrofti. Although LF is not associated with
significant mortality, its attendant debilitating ‘acute attacks’ and
disfiguring chronic manifestations (primarily hydrocoele, lymph-
oedema and elephantiasis) cause suffering and social stigma to the
affected individuals and impedes economic performance [1–3].
Globally, LF affects an estimated 120 million people, out of whom
44% are in Sub-Saharan Africa, and LF has been ranked as one of
the world’s leading causes of permanent and long-term disability
[4,5]. The major burden of LF is found in rural areas, but it is also
endemic in less developed peri-urban and urban areas [6].
In 1997, the World Health Assembly passed a resolution calling
for global elimination of LF as a public health problem. The
World Health Organization subsequently launched the Global
Programme to Eliminate Lymphatic Filariasis (GPELF) with the
major goal to eliminate LF as a public health problem by the year
2020 [7]. The programme has a twofold aim of interrupting
transmission by annual mass drug administration (MDA) and
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alleviating suffering and disability by applying measures for
morbidity control. MDA is based on annual distribution of a
single dose of albendazole in combination with either diethylcar-
bamazine or ivermectin to all eligible individuals, with the main
purpose to kill circulating microfilarae produced by the adult
worms, and thereby reduce the level of transmission in the
endemic communities. In addition to eliminate the microfilariae
from the blood, these drug combinations have beneficial effects by
reducing the burdens of intestinal helminths and ectoparasites in
those treated [4,8]. To achieve the goal of elimination of LF as a
public health problem, it is crucial that a major proportion in the
target community adhere to treatment and take the offered tablets
once a year for a period of 5 to 6 years [4,9], which is believed to
correspond to the reproductive lifespan of the adult parasitic
worms. A minimum effective population drug uptake rate is
considered to be 65% [10]. However, there are many challenges in
reaching such high coverage [11], and studies from LF control
programmes in different parts of the world indicate that drug
uptake rates are often suboptimal [12–18].
LF is widespread in Tanzania [19], and especially the coastal
areas and areas around the great lakes are characterized by high
levels of infection and disease [20–24]. It is estimated that over 34
million individuals live in endemic foci in Tanzania and that 5-6
million individuals are affected by one or more clinical manifes-
tations of LF [25]. The National Lymphatic Filariasis Elimination
Programme (NLFEP) was launched in Tanzania in 2000, and the
first MDA with albendazole and ivermectin was implemented in
endemic areas of Coast Region near Dar es Salaam in the same
year. In 2009, the NLFEP was integrated in the Neglected
Tropical Disease Control Programme (NTDCP), which also
conducts MDA for other neglected tropical diseases. The MDA
activities have gradually expanded, and now cover 17 of the 25
regions in Tanzania Mainland.
Results of previous cross-sectional surveys with focus on MDA
activities in Tanzania have reported suboptimal drug coverage
rates within the range of 31–62% [26–28]. However, the absence
of detailed information on both programme/provider related
factors and individual predictors for drug uptake is presently a
main barrier for an informed discussion on how to improve and
optimize MDA strategies in order to increase overall drug
coverage rates. The present study comprises a component of a
larger Tanzanian research project with the main aim of describing
and analyzing MDA activities in order to develop improved
programme strategies for control of LF and other neglected
parasitic infections. The overall objective of the present study was
to assess, through household questionnaires, the associations
between selected predictors and individual drug uptake shortly
after the implementation of MDA in two rural and two urban
districts in Tanzania.
Methods
Study areas
The study was carried out in Lindi and Morogoro regions,
Tanzania (Figure 1). From both regions a rural and an urban
district were included. The selected urban districts were those
enclosing the regional capitals (Lindi and Morogoro towns),
whereas the rural districts were purposively selected among those
neighboring the urban district.
Lindi Region is located along the Indian Ocean coast in south-
eastern Tanzania (Figure 1). The region is divided into six
districts. Among these, Lindi Municipality (in the following called
Lindi Urban) and Lindi Rural were included in the study, which
took place in May 2011. Lindi Urban is about 470 km south of
Dar es Salaam, and administratively it is divided into 13 wards. Six
wards (4 central and 2 peri-urban; Rahaleo, Matopeni, Naching-
wea, Mwenge, Mtanda and Msinjahili, respectively) with a total
population of 23,747 were selected for the study. Lindi Rural is
surrounding Lindi Urban to the North, West and South and is
divided into 28 wards. The main ethnic groups in the district are
the Yao, Mwera and Makonde. Agriculture forms the mainstay of
economic activities in the district, whereas small-scale sea-fishing is
practiced among those living along the sea. One ward (Nachunyu),
with a population of 9713 and located approximately 75 km south
of Lindi town, was selected for the study.
Morogoro Region is located more inland, in the eastern/central
part of Tanzania (Figure 1), and is divided into 7 districts. Among
these, Morogoro Municipality (in the following called Morogoro
Urban) and Morogoro Rural were included in the study, which
took place in August 2011. Morogoro Urban is located at the base
of the Uluguru Mountains about 210 km to the east of Dar es
Salaam and is divided into 19 wards. Three wards (two central and
one peri-urban; Kingo, Kichangani and Kingolwira, respectively)
with a total population of 44,063 were selected for the study.
Morogoro Rural is located in the north-eastern part of Morogoro
Region and is divided into 25 wards. The main ethnic groups in
the district are Luguru, Kutu and Zigua, but pastoral Masai and
Sukuma are also common. The majority of inhabitants are
engaged in farming, growing both subsistence and cash crops,
while other activities include fishing, forestry and small scale
business. One ward (Mngazi), with a population of 9,528 and
located approximately 120 km south of Morogoro town was
selected for the study.
LF control activities in the study areas
The National Lymphatic Filariasis Elimination Programme
(NLFEP) in Tanzania is administering MDA with a combination
of ivermectin (150–200 mg/kg body weight) and albendazole
(400 mg) to individuals aged $5 years in LF endemic areas. After
integration of the NLFEP in the Neglected Tropical Diseases
Control Programme (NTDCP) in 2009, the MDA activities for LF
were combined with mass treatment programmes for other
neglected tropical diseases (NTDs). For the districts included in
the present study the other activities include annual school based
praziquantel treatment for schistosomiasis and annual community
based treatment with anzithromycin for trachoma (the last activity
not in Lindi Urban), usually implemented two weeks after the
MDA for LF. In principle, MDA for LF is carried out as
community directed treatment, with the drug distributors being
selected by the general community. However, in some cases drug
distributors are selected by village leaders or health personnel from
nearby health facilities.
MDA for control of LF was implemented in Lindi Region
(including the present study areas) in 2003, 2004 and 2005 after
which the activities stopped due to financial constraints and the
consolidation into the integrated NTDCP. The MDA for LF in
May 2011 (prior to the present study) was therefore carried out
after a period of 6 years without MDAs.
In parts of Morogoro Region, Community Directed Treatment
with Ivermectin (CDTI) for control of onchocerciasis has been
carried out since 1997. Morogoro Rural was covered by this
activity in 2004 and 2006 only whereas Morogoro Urban was not
included at all. MDA for control of LF started in 2007 in
Morogoro Rural and in 2009 in Morogoro Urban, as part of the
expanded mandate of the African Programme of Onchocerciasis
Control (APOC) to NTDs, and has been implemented annually
since then. The MDAs for LF in July 2011 (prior to the present
study) were thus rounds 5 and 3 in these districts, respectively.
Drug Uptake in MDA for LF Control
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Study design
The study was cross-sectional and questionnaire-based with a
main focus on self-reported information on drug uptake shortly
after the 2011 rounds of MDA for LF. The investigators and
interviewers were not associated with the MDA staff or engaged in
MDA activities. Clusters of households were prior to implemen-
tation of MDA activities randomly selected in all four study sites
using a multi-stage cluster-based sampling strategy. Results of a
sample size calculation indicated that in each of the four study sites
an appropriate sample of 980 individuals aged $15 years was
needed. However, a large number of individuals had to be
excluded after data had been gathered, specifically from Morogoro
Rural, since they had been interviewed prior to the drug
distribution. Despite the exclusions we did not encounter results
of statistical analysis, which suggest lack of power in our analyses.
For the selected study wards in both districts of Lindi Region,
the treatment registers prepared by the NTD Control Programme
for the 2011 MDA for LF were used for random selection of
households to be included in the present study. For both study
districts in Morogoro Region, the treatment registers prepared by
the NTD Control Programme for the 2011 MDA had not been
properly updated and therefore were unsuitable for the present
study. Instead, a number of neighborhoods/hamlets (administra-
tive units below the ward level in urban and rural areas,
respectively) were randomly selected from the study wards, and
all households (and their inhabitants) in these units were registered
during house to house visits. Households were thereafter randomly
selected for the study. From all four districts, households were
selected to give a study population of approximately 1000
individuals aged $15 years. It was later realized that a proportion
of the selected households in Morogoro Rural had been
interviewed for the present study prior to drug distribution.
Therefore, all inhabitants from this study site who said their
household had not been offered drugs were subsequently excluded
from the study.
Questionnaire and interviews
The questionnaire included questions on age, gender, socio-
economic indicators (educational status, ownership of household
items, household ownership status), religion, drug intake during
the 2011 MDA round, reasons for taking/not taking drugs, and
participation in previous MDA activities for LF control. The
questionnaire was initially developed in English, translated into
Swahili and subsequently back-translated to English for validity
purposes. The questionnaire was pilot-tested in Morogoro Region
and subsequently revised.
Figure 1. Map showing the location of the study sites in Lindi and Morogoro Region, Tanzania. Red = the two urban study districts;
Green = the two rural study districts; Yellow = remaining parts of the two study regions; DSM = Dar es Salaam.
doi:10.1371/journal.pone.0109316.g001
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In all four study areas, the interviews were carried out 3–9 days
after distribution of drugs. In each visited household, individuals
aged $15 years were approached and requested to participate in
the interview after the interviewers had explained the outline and
purpose of the research and asked for their consent. In order to
include all registered members of a household, the interviewers
made up to three visits to the same household. During the first
visit, the interviewer also collected data on the number, age and
sex of children aged 5–14 in the household, and whether they had
taken the drugs during the MDA.
Data analysis
Double entry of data and subsequent quality control of entries
and data analysis were carried out using EpiData (version 3.1) and
SPSS 20 (IBM version 20.0), respectively (Table S1-S4). During
data analysis, individuals were divided into three age groups (15–
29 years, 30–49 years and $50 years). Educational status was also
divided into three groups: Primary education not completed,
primary but not secondary education completed, and secondary
education completed. Individual wealth scores were calculated
based on whether at least one household member owned a radio (2
points), a bicycle (4 points), a television (6 points), a motorcycle (8
points) or a car (10 points). The sum of points was calculated and
categorized into a low (0 points), medium (2–6 points) or high ($7
points) wealth index for the individual.
Groups were compared statistically by Chi-square tests and
oneway ANOVA, as appropriate. Bivariate and multivariate
analyses were used to calculate strength of statistical associations
presented as odds ratios (ORs) between predictors and self-
reported drug uptake. Since the number of interviewed individuals
varied between the households, a generalized estimating equation
(GEE) model was used to compensate for a possible cluster effect of
drug uptake in households and at the same time adjust the
associations for the confounding effects of other co-variables.
Ethical statement
All individuals were asked to give informed verbal consent prior
to interviews, and parents/guardians were asked for permission to
interview individuals ,18 years. Their verbal consent to
participate and/or to allow their minors to participate was
recorded in each questionnaire form. Verbal consent is the
traditional way for making agreements in the study areas, whereas
written consent is unfamiliar and would cause distrust of true
intentions and refusal to participate. Research and ethical
clearance for the study (including the use of verbal informed
consent) was provided by the Medical Research Coordinating
Committee of the National Institute for Medical Research,
Tanzania (reference number NIMR/HQ/R.8a/Vol. IX/1073).
Results
Study population
The initial selection provided a total eligible population of 4053
adult individuals aged $15 years from the 4 districts combined,
and 4003 (98.8%) of these were interviewed. However, 350
individuals subsequently had to be excluded due to incomplete or
inconsistent data (age, gender, drug uptake data missing; or
contradictions between data on drug uptake and drug related
statements), and 374 individuals from Morogoro Rural had to be
excluded because interviews were performed prior to drug
distribution. Hence, the total valid study sample included in the
analyses was 3279 adults (80.9% of the eligible population) from
747 households. Among these, 812, 1123, 429 and 915 were from
Lindi Rural, Lindi Urban, Morogoro Rural and Morogoro Urban,
respectively (Table 1). Overall, the mean age was 36.9 years, there
were more females (64.2%) than males (35.8%), there were more
Muslims (72.2%) than Christians (26.5%), and these characteristics
differed significantly between the four districts (Table 1).
In addition to the interviewed adult population, information
about drug uptake was obtained from parents/caretakers for a
total of 1942 children aged 5–14 years (Table 1). Of these, 922
(47.5%) were girls and 1020 (52.5%) were boys, and their mean
age was 9.3 years.
Drug uptake
The drug uptake rates among the interviewed adults and the
children from the same households in the four districts are shown
in Table 1. The overall drug uptake rate for all individuals (adults
and children) and all four districts combined was 55.1%. Overall,
the rate was higher in Morogoro Region (68.1%) than in Lindi
Region (45.0%). The highest and lowest rates were observed in
Morogoro Urban (75.6%) and Lindi Urban (44.5%), respectively.
In three of the four districts there were no major differences in
drug uptake rates between children and adults. However, in
Morogoro Rural, the drug uptake rate was considerably higher in
the adults (61.1%) than in the children (48.6%).
The drug uptake rates among the interviewed adults by selected
variables for each of the four districts are presented in Table 2.
Whereas Morogoro Rural had significantly higher drug uptake
rates for females than for males, the opposite was the case for
Morogoro Urban. No significant differences were seen between
females and males in the two districts of Lindi. Drug uptake rates
increased significantly with increasing age in three of the districts,
whereas this was not the case in Morogoro Rural (Table 2). In
both districts of Morogoro, there was a significant trend of higher
drug uptake rates among those who had completed primary school
than among those who had not, but such trend was not seen in the
two Lindi districts. With the exception of Morogoro Urban, where
individuals with medium-high wealth index had significantly
higher drug uptake rates than those with a low wealth index, drug
uptake rates showed no relation to wealth index in the other three
districts. In both districts of Morogoro, individuals who stayed in
rented households had higher drug uptake rates than those who
stayed in households with another status (very few or none stayed
in rented households in the two Lindi districts). In Morogoro
Urban, there was a significantly higher drug uptake rate among
Muslims than among Christians, whereas drug uptake rates
showed no relation to religion in any of the other three districts.
The most persistent and statistically significant trend in drug
uptake rates, which was observed across all four districts, was the
relationship to previous history of drug uptake. In all four districts
the drug uptake rate increased with number of previous times the
individuals had participated in MDA. In e.g. Morogoro Urban the
drug uptake rate among individuals who had not previously taken
drugs was 46.9% but it increased to 95.7% among individuals who
had taken drugs three times or more prior to the current MDA.
Results of bivariate and multivariate analysis of predictors for
drug uptake among the interviewed adults from all four study sites
combined are shown in Table 3. After adjusting for confounding
and the potential cluster effect of household exposure, the results
of the GEE model indicated that age group, renting a house and
history of previous drug uptake remained as statistically significant
predictors for drug uptake. Hence, individuals in the age groups
30–49 years or $50 years were approximately 30–40% more
likely to take drugs as compared to individuals in the age group
15–29 years. To live in a rented house or apartment as compared
to being an owner of a house or apartment more than doubled the
chance of taking drugs. The strongest statistically significant
Drug Uptake in MDA for LF Control
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predictor for drug uptake was previous history of drug uptake.
Hence, an individual who prior to the last distribution of drugs
had taken drugs twice, or three times or more, was about 2–3
times more likely to take drugs during the present round of MDA
as compared to an individual who had not taken drugs before.
According to the interviewed adults who had taken the drugs,
the vast majority of drug distributions (93.0%) had taken place in
individual’s homes, whereas 4.4% had been offered drugs from a
central point in the target community (Table 4). The majority of
drug distributors were reported to be community members
(77.6%), but almost 10% of the interviewed individuals reported
that they did not know the drug distributor. The vast majority of
individuals who had taken drugs (95.0%) reported that their main
reason for doing so was to protect themselves against LF.
Reasons for not taking drugs
Being absent from home during drug distribution was the most
common reason given for not taking drugs and was reported by
50.2% of the individuals who did not take drugs during the last
round of MDA (Table 5). This proportion corresponds to 21.9%
of the total population not being at home when drug distributions
were carried out (Figure 2). 10.6% of non-participants reported
that tablets were never distributed to them, whereas 10.8%
reported that they were excluded from treatment due to their
condition (i.e. disease or pregnancy), and 9.0% reported that they
were not informed about the drug distribution and therefore did
not receive the drugs. Furthermore, 7.6% of the individuals who
did not take drugs reported a general dislike for the drugs as the
main reason for not taking them, 3.9% mentioned that they did
not consider the drugs as being effective and 4.6% were worried
about side effects.
Discussion
The present study analysed factors influencing drug uptake in
four districts of Tanzania shortly after implementation of MDA in
2011. When considering a recommended drug uptake rate of 65%
or higher in order to interrupt transmission [10], the observed
drug uptake rates in three of the four study districts were
suboptimal. Lower than recommended drug uptake rates have
similarly been reported from other LF control programmes in e.g.
Sri Lanka [12], the Philippines [13], India [14,16,29], American
Samoa [15], Kenya [17] and Ghana [18], as well as from previous
studies on the LF control programme in Tanzania [27,28], and
may considerably prolong the time needed to reach the goal of LF
transmission elimination [9]. It is of great importance to identify
the barriers to optimal drug uptake rates in order to be able to
improve on the rates and thereby secure successful LF control.
The overall questionnaire participation rate was high. A
number of respondents subsequently had to be excluded from
the analyses because the interviews were mistakenly performed
prior to drug distribution (Morogoro Rural) or because of missing
or contradicting data. However, it is unlikely that these exclusions
have caused selection bias to the extent of significantly affecting
the measured drug uptake rates and/or the results of the statistical
analyses. Females accounted for a much higher proportion of the
respondents than males at all study sites. This to some extent
reflects the demographic profile in the study areas, where females
outnumber males [30]. The gathered data were based on self-
reported information. In order to minimize interviewers bias,
including social desirability bias, comprehensive pilot testing and
subsequent revisions of the questionnaires was performed prior to
data collection, and the general impression was that the
respondents were very eager to share their views and experiences
with the researchers. Since the interviews were performed shorty
after drug distribution it is likely that the influence of recall bias
was also limited.
Table 1. Characteristics of the interviewed adult study populations and their children from the four study sites in Lindi and
Morogoro Region, and the reported drug uptake rates.
Lindi Rural Lindi Urban Morogoro Rural Morogoro Urban Total P-value
Interviewed adults ($15 years)
No. adults 812 1123 429 915 3279 -
Female: male ratio 1.45 2.26 1.25 1.98 1.80 ,0.001*
Mean age in years 37.3 37.2 38.7 35.2 36.9 ,0.001**
No. households 164 226 162 195 747 -
Mean no. individuals/household (range) 4.89 (1–17) 4.94 (1–12) 2.64 (1–6) 4.66 (1–19) 4.76 (1–19) -
Muslim: Christian ratio 15.8 5.3 1.1 1.0 2.7 ,0.001*
No. of adults taking the drugs (%) 379 (46.7) 497 (44.3) 262 (61.1) 672 (73.4) 1810 (55.2) ,0.001*
Children from same households (5–14 years)
No. children 455 679 259 549 1942 -
Female: male ratio 0.94 0.93 1.02 0.79 0.90 NS*
Mean age in years 8.7 9.4 9.4 9.6 9.3 ,0.001**
No. of children taking the drugs (%) 200 (44.0) 304 (44.8) 126 (48.6) 435 (79.2) 1065 (54.8) ,0.001*
Adults and children combined
No. individuals 1267 1802 688 1464 5221 -
No. of individuals taking the drugs (%) 579 (45.7) 801 (44.5) 358 (52.0) 1107 (75.6) 2875 (55.1) ,0.001*
*) Chi-square test.
**) Oneway ANOVA.
doi:10.1371/journal.pone.0109316.t001
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The higher levels of drug uptake in districts in Morogoro
Region as compared to Lindi Region may be due to the more
extensive previous experience with MDA activities in Morogoro
Region, resulting in improved planning, more effective social
mobilization and higher overall quality of drug distribution,
including better timing and higher proportion of households
covered by drug distributors. In Morogoro Urban the mobilization
campaign moreover included the use of local radio and television
stations, which offered their services to the programme free of
charge. In this context, it was interesting that the highest drug
uptake rate was observed in Morogoro Urban, in contrast to the
common finding that drug uptake rates are lower in urban as
Table 4. Answers to questions related to drug uptake among the interviewed adult study populations from the four study sites in
Lindi and Morogoro Region who reported to have taken the drugs.
Question/answer No. individuals (% of those who took the drugs)
Lindi Rural Lindi Urban
Morogoro
Rural
Morogoro
Urban Total
Where were you offered the drugs? (n = 1681)
Brought to my home 280 (91.8) 424 (90.8) 235 (94.0) 624 (94,7) 1563 (93.0)
From a central point in our community 23 (7.5) 33 (7.1) 8 (3.1) 10 (1.5) 74 (4.4)
From a health facility 1 (0.3) 7 (1.5) 4 (1.6) 9 (1.4) 21 (1.2)
From my work place 0 (0.0) 0 (0.0) 0 (0.0) 10 (1.5) 10 (0.6)
From my school 0 (0.0) 2 (0.4) 1 (0.4) 3 (0.5) 6 (0.4)
Other 1 (0.3) 1 (0.2) 2 (0.8) 3 (0.5) 7 (0.4)
Who distributed the drugs? (n = 1784)
Community members selected by community 287 (77.6) 337 (69.1) 229 (88.0) 531 (79.7) 1384 (77.6)
Health facility staff, community health worker, village leader 28 (7.5) 84 (17.2) 9 (3.5) 104 (15.6) 225 (12.6)
Don’t know the distributor 55 (14.9) 67 (13.7) 22 (8.5) 31 (4.7) 175 (9.8)
Reason for taking the drugs (n = 1791)
To protect myself against LF 354 (93.9) 465 (93.9) 248 (96.9) 635 (95.8) 1702 (95.0)
Other (e.g. instructed by leaders, because they are free) 23 (6.1) 30 (6.1) 8 (3.1) 28 (4.2) 89 (5.0)
doi:10.1371/journal.pone.0109316.t004
Figure 2. Reasons given for not taking the drugs. Shown for the combined interviewed adults ($15 years) from the four study sites in Lindi and
Morogoro Region. Expressed in percent of all interviewed individuals irrespective of whether they took the drugs or not (n = 3213).
doi:10.1371/journal.pone.0109316.g002
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compared to rural areas [12,14,16,31,32]. There was no clear
overall difference in drug uptake rates between children and adults
or between males and females, which may suggest that when one
or several adult members in a household accept to take the drugs,
the majority of the remaining household members will also do so.
Similarly, no clear overall association was observed between drug
uptake and individual educational level or household proxy
indicators for socio-economic status. Assuming that lower educa-
tional or socio-economic levels are associated with a poorer
knowledge about LF and its control, then the findings in the
present study suggests that lack of this knowledge may not be a
major barrier for drug uptake.
The GEE analysis showed that the major overall statistically
significant predictors for drug uptake among the respondents were
increasing age, living in a rented home and previous drug uptake
in earlier rounds of MDA. After adjusting for other factors,
including exposure to drug uptake in previous rounds of MDA,
increasing age was associated with increasing levels of drug
acceptance. This may reflect that older individuals are more
motivated to take the drugs than the younger ones. To live in a
rented home was also strongly associated with drug uptake. This
trend was observed in both rural and urban districts of Morogoro
Region, a region characterized by economic growth and a high
influx of seasonal migrant workers, which has resulted in many
houses and rooms being offered for rent. In contrast, very few
individuals in Lindi Region lived in rented homes. The rented
homes were primarily occupied by migrant workers originating
from other parts of Tanzania, who were often more well off and
better educated than the local population. Their perceptions and
practices in relation to MDA apparently differed systematically
from the rest of the population, thus leading to a higher level of
drug uptake.
The strongest predictor for individuals to take drugs was
previous history of drug uptake. Hence, individuals who had taken
drugs three times or more prior to the present MDA were almost
three times more likely to take drugs as compared to those who
had not taken drugs before. This finding suggests that individuals
who have already experienced the ancillary benefits of taking
drugs, e.g. experiences with expulsion of Ascaris worms from the
body [4,11], and/or who gradually have obtained an increased
level of acquaintance with and understanding of the principle of
MDA are more motivated to take the drugs again during
subsequent rounds of MDA. In this respect, a study in Kenya
similarly showed that uptake of drugs was strongly associated with
willingness to take drugs in future MDA rounds [17]. The findings
of the present study moreover suggest that a small proportion of
individuals for various reasons persistently refuse to take the drugs
during MDA activities. These ‘‘systematic non-compliers’’ are a
major problem to the control programmes as they serve as a
continued source of infection for LF transmission in their
community [11,32,33].
For the MDA providers in the control programme it is a major
challenge to disseminate the message to the endemic population
that the potential key LF health benefit is elimination of
transmission rather than clearance of adult filarial worms in
already infected individuals. Obviously, this complicated message
is difficult to comprehend by the recipients. This was also seen in
the present study where the most commonly reported reason for
taking drugs was that treatment would protect the recipient against
LF. This may also be the reason why the most commonly reported
reason for taking drugs in the present study was that treatment
would provide immediate personal protection of the recipient
against LF. If this assumption is correct it is a concern that a partly
incorrect perception of drug benefits is the main motivating factor
for drug uptake.
The vast majority of respondents who took the drugs reported
that drugs were offered to them in their homes. In this context, it is
important to notice that being absent from home during time of
drug distribution was the most common reason for not taking
drugs, and accounted for more than 50% of all drug non-uptakes.
This unfortunate occurrence was partly due to poor timing of drug
distribution, e.g. in Lindi Rural drugs were distributed during
harvest time – a period when many people are occupied in their
farms. Another reason was poor communication from providers
regarding the actual time of drug distribution, which resulted in
many individuals waiting in vain for extended periods in their
homes, where after they decided to leave before the drug
distributor reached their part of the community (observed in a
qualitative component of the present research project which will
be reported elsewhere). The qualitative study component more-
over revealed that some individuals, who already had made a
decision not to take the drugs, deliberately left their homes at the
time of drug distribution in order to avoid an encounter with the
drug distributor, as also reported by others [27]. Other important
provider-related reasons were given for not taking drugs, namely
that the drugs were not distributed in their area, and that the
Table 5. Reasons given for not taking the drugs among the interviewed adult study populations from the four study sites in Lindi
and Morogoro Region who reported not to have taken the drugs (n = 1403).
Reason Number individuals (% of those who did not take the drugs)
Lindi Rural Lindi Urban Morogoro Rural* Morogoro Urban Total
Absent from home during drug distribution 249 (59.6) 288 (49.3) 61 (37.4) 107 (45.0) 705 (50.2)
Drugs were not distributed 69 (16.5 39 (6.7) - 41 (17.2) 149 (10.6)
Not allowed to take the drugs because of my condition 26 (6.2) 67 (11.5) 37 (22.7) 22 (9.2) 152 (10.8)
Not informed about distribution 42 (10.0) 31 (5.3) 21 (12.9) 32 (13.4) 126 (9.0)
Did not like the drugs 20 (4.8) 71 (12.2) 1 (0.6) 14 (5.9) 106 (7.6)
Worried about side effects 6 (1.4) 36 (6.2) 16 (9.8) 6 (2.5) 64 (4.6)
Don’t think the drugs are effective 3 (0.7) 36 (6.2) 7 (4.3) 9 (3.8) 55 (3.9)
Had taken alcohol 1 (0.2) 5 (0.9) 1 (0.6) 1 (0.4) 8 (0.6)
Other reasons 2 (0.4) 11 (1.9) 19 (11.7) 6 (2.5) 38 (2.7)
*) The 374 individuals from Morogoro Rural who reported not to have been offered drugs were excluded from the study (see Methods).
doi:10.1371/journal.pone.0109316.t005
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recipients were not informed about the distribution. Similar
observations have been reported from other studies
[12,14,17,18,29,31].
According to guidelines from the World Health Organization, a
drug uptake rate of 65% or higher is required in order to eliminate
transmission of LF [10]. The drug uptake rates observed in three
of the four sites of the present study were lower or much lower
than this. Unless steps are taken to increase drug uptake rates
across endemic areas it is unlikely that the MDA programme will
reach the target of elimination within reasonable time. In this
respect, the findings of the present study provide useful insights for
informed decisions on how to optimize drug delivery strategies.
The findings strongly indicate that drug uptake relies more on
easily modifiable provider-related factors than on individual
perceptions and practices in the target population. Thus, limited
investments in appropriate timing of drug distribution, dissemina-
tion of accurate information about the timing to recipients, and
motivation of drug distributors to visit all households in the target
areas (with repeat visits to households where inhabitants are not
found at home during first visit) could potentially increase drug
uptake considerably. This may be implemented by using a strategy
that frequently monitors the programme performance and make
appropriate adjustments. For this purpose, the Quality of Care
model [34] developed by the World Health Organization provides
a simple framework for engaging the various stakeholders,
including representatives from different parts of the community,
in the planning and implementation of an intervention in order to
ensure a predefined level of quality. By using such systematic
approach and by involving local decision makers, programme
planners, drug distributors and community members, the MDA
programmes targeting LF in Tanzania and elsewhere should be in
a good position to increase drug uptake rates and thereby reach
the target of global elimination of LF as a public health problem.
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